Apoorva Ambavane

机构：University of Dubai · ORCID：0000-0001-5887-792X

发表论文 46 篇 · 总被引 382 次 · h-index 10

代表论文

• Clinical and Economic Outcomes Associated with Treatment Sequences In Patients With BRAF -Mutant Advanced Melanoma (2018 · Immunotherapy · 被引 35)
• Treatment sequences for advanced renal cell carcinoma: A health economic assessment (2019 · PLoS ONE · 被引 19)
• Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis (2018 · Annals of Oncology · 被引 19)
• Clinical and Economic Outcomes of Treatment Sequences for Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma (2020 · Immunotherapy · 被引 16)
• Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab (2019 · Advances in Therapy · 被引 15)
• Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring MET ex14 skipping alterations in the United States (2021 · Journal of Medical Economics · 被引 8)